Skip to main content
SpringerLink
Log in

NSCLC: Neoadjuvante oder adjuvante Therapie

Wohin geht die Reise bei lokal fortgeschrittenen Tumoren?

  • Pneumoonkologie
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Song W et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol. 2010;5(4):510-6

  2. NSCLC Meta-analysis Collaborative Group et al. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561-71

  3. Sedrakyan A et al. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. J. Thorac. Cardiovasc. Surg. 2004;128:414-19

  4. Burdett S et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015; (3):CD011430

  5. Lim E et al. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data J Thorac Oncol. 2009; 4(11):1380-8

  6. Blumenthal GM et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer J Thorac Oncol. 2018; 13(12):1818-31

  7. Ou W et al. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer. J Thorac Oncol. 2010; 5(7):1033-41

  8. Fukumoto S-I et al. A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703). Cancer Chemother Pharmacol. 2020; 86(1):117-27

  9. Forde PM et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 386(21):1973-85

  10. Ge S et al. Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis. 2022;14(2):333-42

  11. Ulas EB et al. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. ESMO Open. 2021;6(5):100244

  12. Romero Román A et al. Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer. Eur J Cardiothorac Surg. 2021;14;60(1):81-8

  13. Liang W et al. International expert consensus on immunotherapy for early-stage non-small cell lung cancer. Transl Lung Cancer Res. 2022;11(9):1742-62

  14. Sepesi B et al. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022; 164(5):1327-37

  15. Bott MJ et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019; 158(1):269-76

  16. Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021; 398(10308):1344-57

  17. Wakelee H et al. PL03.09 IMpower010: Overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC. J Thorac Oncol. 2022; https://doi.org/10.1016/j.jtho.2022.07.013

  18. O`Brien et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial Lancet Oncol. 2022; 23:1274-86

  19. Wu Y-L et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383(18):1711-23

Download references

Author information

Authors and Affiliations

  1. Klinik für Internistische Onkologie & Hämatologie mit integrierter Palliativmedizin, KEM | Evang. Kliniken Essen-Mitte gGmbH, Henricistr. 92, 45136, Essen, Deutschland

    Daniel C, Christoph

  2. Klinik für Thoraxchirurgie, KEM | Evang. Kliniken Essen-Mitte, Henricistr. 92, 45136, Essen, Deutschland

    Jan Volmerig

Authors
  1. Daniel C, Christoph
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Volmerig
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

C, Christoph, D., Volmerig, J. NSCLC: Neoadjuvante oder adjuvante Therapie. Im Fokus Onkologie 26, 13–17 (2023). https://doi.org/10.1007/s15015-023-3124-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-023-3124-3

Search

Navigation